Key facts
- This page summarizes Sean Senn's Form 4/A - Amendment filing for Immix Biopharma, Inc. (IMMX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 22 Jul 2022, 16:12.
Sean Senn - 14 Jul 2022 Form 4/A - Amendment Insider Report for Immix Biopharma, Inc. (IMMX)
- Reporting relationship
- Under 10% owner
- Issuer ticker
- IMMX
- Reported as of
- 14 Jul 2022
- Net transaction value
- -$550
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 22 Jul 2022, 16:12:46 UTC
- Original report date
- 18 Jul 2022
- Prior SEC filing
- 18 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ilya Rachman as Attorney-in-Fact for Sean Senn
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sean Senn filed Form 4/A - Amendment for Immix Biopharma, Inc. (IMMX) on 22 Jul 2022.
Change
- Previous filing in this sequence was filed on 18 Jan 2022.
- Current net transaction value: -$550.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMMX
transaction
Common Stock
Sale
- Transaction value
- $550
- Shares
- -200
- Change %
- -0.02%
- Price
- $2.75
- Shares after
- 899,800
- Date
- 14 Jul 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Sean Senn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.